Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>Key 2Q25 takeaways include: 1) CCLD's "AI Center of Excellence" is now fully operational, with senior executives focused on incorporating proprietary AI solutions across operations, products, and services to enhance provider/patient experience, streamline claims coding, improve A/R workflows, and augment denial management efficacy 2) we view the company's recent ONC certification as a key catalyst to increasingly penetrate a $1.5+ billion market spanning ~1,300 Critical Access Hospitals (CAHs) across rural markets needing to upgrade legacy EHR systems 3) in light of disciplined execution, rising operating leverage, and improving financial performance, CCLD maintains ample capacity to continue to reinvest for growth and capitalize on incremental M&A opportunities and 4) while senior executives remain disciplined on pricing and strategic fit, management increasingly views M&A as an attractive path to enter new markets and drive incremental growth via cross-selling services and leveraging existing infrastructure/technology post-acquisition.</li></ul>

Key 2Q25 takeaways include: 1) CCLD's "AI Center of Excellence" is now fully operational, with senior executives focused on incorporating proprietary AI solutions across operations, products, and services to enhance provider/patient experience, streamline claims coding, improve A/R workflows, and augment denial management efficacy 2) we view the company's recent ONC certification as a key catalyst to increasingly penetrate a $1.5+ billion market spanning ~1,300 Critical Access Hospitals (CAHs) across rural markets needing to upgrade legacy EHR systems 3) in light of disciplined execution, rising operating leverage, and improving financial performance, CCLD maintains ample capacity to continue to reinvest for growth and capitalize on incremental M&A opportunities and 4) while senior executives remain disciplined on pricing and strategic fit, management increasingly views M&A as an attractive path to enter new markets and drive incremental growth via cross-selling services and leveraging existing infrastructure/technology post-acquisition.

CareCloud

CCLD: 2Q25 Earnings